Entering text into the input field will update the search result below

Female Viagra developer Palatin Tech exploring potential sale; shares up 5%

  • Nano cap Palatin Technologies (PTN +5.3%) spiked almost 55% before retracing on the news that it is exploring a possible sale. It has retained Greenhill & Co. to advise after receiving multiple offers from interested suitors.
  • Palatin's lead product candidate is bremelanotide, in development for the on-demand treatment of female sexual dysfunction in premenopausal women with hypoactive sexual desire disorder (HSDD). Its key advantage over Valeant Pharmaceuticals' (VRX -8.2%) Addyi (filbanserin) is that women who have consumed alcohol can use it.
  • Valeant bought the company that developed Addyi, Sprout Pharmaceuticals, for $1B but the drug has struggled to gain traction due to, in large part, its contraindication with alcohol because of the risk of fainting.

Recommended For You

About PTN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PTN--
Palatin Technologies, Inc.